BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guixé-Muntet S, Biquard L, Szabo G, Dufour JF, Tacke F, Francque S, Rautou PE, Gracia-Sancho J. Review article: vascular effects of PPARs in the context of NASH. Aliment Pharmacol Ther 2022;56:209-23. [PMID: 35661191 DOI: 10.1111/apt.17046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Leal AF, Fnu N, Benincore-Flórez E, Herreño-Pachón AM, Echeverri-Peña OY, Alméciga-Díaz CJ, Tomatsu S. The landscape of CRISPR/Cas9 for inborn errors of metabolism. Mol Genet Metab 2023;138:106968. [PMID: 36525790 DOI: 10.1016/j.ymgme.2022.106968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ahmed YM, Orfali R, Abdelwahab NS, Hassan HM, Rateb ME, Aboulmagd AM. Partial Synthetic PPARƳ Derivative Ameliorates Aorta Injury in Experimental Diabetic Rats Mediated by Activation of miR-126-5p Pi3k/AKT/PDK 1/mTOR Expression. Pharmaceuticals 2022;15:1175. [DOI: 10.3390/ph15101175] [Reference Citation Analysis]
3 Zhou S, You H, Qiu S, Yu D, Bai Y, He J, Cao H, Che Q, Guo J, Su Z. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR). Biomed Pharmacother 2022;154:113577. [PMID: 35988420 DOI: 10.1016/j.biopha.2022.113577] [Reference Citation Analysis]
4 Ohkoshi-yamada M, Kamimura K, Kimura A, Tanaka Y, Nagayama I, Yakubo S, Abe H, Yokoo T, Sakamaki A, Kamimura H, Terai S. Effects of a selective PPARα modulator, sodium-glucose cotransporter 2 inhibitor, and statin on the myocardial morphology of medaka nonalcoholic fatty liver disease model. Biochemical and Biophysical Research Communications 2022. [DOI: 10.1016/j.bbrc.2022.07.117] [Reference Citation Analysis]